

# PRIOR AUTHORIZATION POLICY

**POLICY:** Oncology – Bosulif Prior Authorization Policy

- Bosulif® (bosutinib tablets and capsules – Pfizer)

**REVIEW DATE:** 05/01/2024; selected revision 06/12/2024

---

## OVERVIEW

Bosulif, a tyrosine kinase inhibitor (TKI), is indicated for the following uses:<sup>1</sup>

- **Chronic myelogenous leukemia (CML)**, Philadelphia chromosome positive (Ph+), in chronic phase in adults and pediatric patients ≥ 1 year of age who are newly-diagnosed or resistant or intolerant to prior therapy.
- **CML**, Ph+, in accelerated, or blast phase, in adults with resistance or intolerance to prior therapy.

## Guidelines

Bosulif is addressed in guidelines from National Comprehensive Cancer Network (NCCN):

- **Acute Lymphoblastic Leukemia (ALL):** NCCN ALL guidelines for adults and adolescents (version 4.2023 – February 5, 2024) recommend Bosulif for Ph+ disease in many different clinical circumstances (e.g., induction, consolidation therapy, maintenance, or relapsed or refractory disease) [category 2A].<sup>2</sup> The guidelines state that the ALL panel considers adolescents to be within the age range of 15-39 years. TKIs in combination with other agents (e.g., chemotherapy or corticosteroids) are recommended for induction therapy for Ph+ ALL. TKIs have also been incorporated into consolidation and maintenance therapy, as well as in the relapsed/refractory setting (category 2A). TKI options include: Bosulif, Sprycel® (dasatinib tablets), imatinib, Tasigna® (nilotinib capsules), or Iclusig® (ponatinib tablets) [category 2A]. NCCN panel notes that not all TKIs have been directly studied within the context of each specific regimen and there are limited data for Bosulif in Ph+ ALL. Use of a specific TKI should account for anticipated/prior TKI intolerance and disease-related features. For adults and adolescents, Iclusig has activity against T315I mutations and/or in whom no other TKI is indicated (category 2A).
- **CML:** NCCN guidelines (version 2.2024 – December 5, 2023) recommend Bosulif as a “preferred” primary regimen for newly diagnosed chronic phase Ph+ CML in patients with a low, intermediate-, or high-risk score (category 1).<sup>3</sup> Bosulif is also recommended as a: “preferred” regimen for patients with advanced phase or blast phase CML (category 2A); an alternative TKI treatment (after primary treatment with imatinib, Sprycel, or Tasigna (category 2A); in a variety of other situations, including post-allogeneic hematopoietic stem cell transplantation (HSCT) [category 2A].
- **Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions:** NCCN guidelines (version 1.2024 – December 21, 2023) recommend Bosulif as “other recommended regimens” for patients with *ABL1* rearrangements (category 2A).<sup>4</sup> It is also recommended as treatment in combination with ALL- or acute myeloid leukemia-type induction chemotherapy followed by allogeneic HSCT (if eligible) for lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia and *ABL1* rearrangement in blast phase (category 2A).

## POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Bosulif. All approvals are provided for the duration noted below.

05/01/2024

© 2024. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

**Automation:** None.

## **RECOMMENDED AUTHORIZATION CRITERIA**

Coverage of Bosulif is recommended in those who meet one of the following criteria:

### **FDA-Approved Indication**

1. **Chronic Myeloid Leukemia.** Approve for 1 year if the patient meets BOTH of the following (A and B):
  - A) Patient is  $\geq 1$  year of age; AND
  - B) Patient has Philadelphia chromosome-positive chronic myeloid leukemia.

### **Other Uses with Supportive Evidence**

2. **Acute Lymphoblastic Leukemia.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):
  - A) Patient is  $\geq 15$  years of age; AND
  - B) Patient has Philadelphia chromosome-positive acute lymphoblastic leukemia; AND
  - C) Patient has tried at least one other tyrosine kinase inhibitor for Philadelphia chromosome-positive acute lymphoblastic leukemia.  
Note: Examples include imatinib and Sprycel (dasatinib tablets).
3. **Myeloid/Lymphoid Neoplasms with Eosinophilia.** Approve for 1 year if the patient meets BOTH of the following (A and B):
  - A) Patient is  $\geq 18$  years of age; AND
  - B) The tumor has an *ABL1* rearrangement.

## **CONDITIONS NOT RECOMMENDED FOR APPROVAL**

Coverage of Bosulif is recommended in those who meet the following criteria:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

## **REFERENCES**

1. Bosulif® tablets and capsules [prescribing information]. New York, NY: Pfizer; September 2023.
2. The NCCN Acute Lymphoblastic Leukemia Clinical Practice Guidelines in Oncology (version 4.2023 – February 5, 2024). © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on April 29, 2024.
3. The NCCN Chronic Myeloid Leukemia Clinical Practice Guidelines in Oncology (version 2.2024 – December 5, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on April 29, 2024.
4. The NCCN Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion Clinical Practice Guidelines in Oncology (version 1.2024 – December 21, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on April 29, 2024.

